All In Biotech

Drug Trial Radar · NCT05573477

Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes

A Randomized, Active-controlled, Double-blind, Parallel, Multi Center, Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated ATB-1011 and ATB-1012 in Patients With Essential Hypertension and Type II Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 255 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

255

Actual

Start

Nov 16, 2022

Primary completion

Aug 31, 2025

Study completion Feb 28, 2026

Sponsor

Lead sponsor
AutotelicbioIndustry
Sponsor type
Industry
First posted
Oct 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate safety and efficacy of ATB-1011 and ATB-1012 co-administration in patients with essential hypertension and type II diabetes mellitus

Conditions

  • Essential Hypertension
  • Diabetes Mellitus, Type 2

Interventions

  • ATB-1011Drug

    Oral tablet

  • ATB-1012Drug

    Oral tablet

  • ATB-1013Drug

    Oral tablet

  • ATB-1011 placeboDrug

    Placebo matched to ATB-1011

  • ATB-1012 placeboDrug

    Placebo matched to ATB-1012

  • ATB-1013 placeboDrug

    Placebo matched to ATB-1013

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean sitting systolic blood pressure (MSSBP) (ATB-1011+ATB-1012 vs. ATB-1012)Time frame: baseline to Week 12
  2. Hemoglobin A1c (HbA1c) (ATB-1011+ATB-1012 vs. ATB-1011)Time frame: baseline to Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.